J_Acquir_Immune_Defic_Syndr[Jour]AND84[volume]AND1[issue]
获得性免疫缺陷综合症杂志84卷1期
1
BriefReport:VirologicResponsebyBaselineViralLoadWithDolutegravirPlusLamivudinevsDolutegravirPlusTenofovirDisoproxilFumarate/Emtricitabine:PooledAnalysis.
简要报告：多乐特加拉米夫定与多乐特加富马酸替诺福韦/恩曲西他滨基线病毒载量的病毒学反应：汇总分析。
EronJ,HungCC,BarilJG,SlimJ,FalcóV,BognerJ,MaggioloF,MillsA,SieversJ,ManCY,UrbaityteR,UnderwoodM,TenorioAR,PappaKA,WynneB,KoteffJ,GartlandM,SmithKY,AboudM.
JAcquirImmuneDeficSyndr.May1;84(1):60-65.
2
Raltegravir(RAL)inNeonates:Dosing,Pharmacokinetics(PK),andSafetyinHIV-1-ExposedNeonatesatRiskofInfection(IMPAACTP).
新生儿雷特格拉维（RAL）：HIV-1感染风险新生儿的剂量、药代动力学（PK）和安全性（IMPAACTP）。
ClarkeDF,AcostaEP,CababasayM,WangJ,ChainA,TepplerH,PopsonS,GrahamB,SmithB,HazraR,CalabreseK,BrysonY,SpectorSA,LommerseJ,MirochnickM;IMPAACTPProtocolTeam.
JAcquirImmuneDeficSyndr.May1;84(1):70-77.
3
Con
